Bone Metastasis - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 107 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bone Metastasis - Pipeline Review, H2 2016, provides an overview of the Bone Metastasis (Oncology) pipeline landscape.

Bone metastasis occurs when cancer cells spread from their original site to a bone. Signs and symptoms of bone metastasis include bone pain, broken bones, urinary incontinence, bowel incontinence and weakness in the legs. The predisposing factors include certain kinds of cancer (breast, prostate, lung, thyroid, and kidney cancers). Treatment options for bone metastasis are chemotherapy, surgery and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bone Metastasis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Bone Metastasis (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bone Metastasis (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bone Metastasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 2, 17 and 1 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 1 molecules, respectively for Bone Metastasis.

Bone Metastasis (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Bone Metastasis (Oncology).
- The pipeline guide reviews pipeline therapeutics for Bone Metastasis (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bone Metastasis (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bone Metastasis (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bone Metastasis (Oncology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bone Metastasis (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bone Metastasis (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Bone Metastasis Overview 9
Therapeutics Development 10
Pipeline Products for Bone Metastasis - Overview 10
Pipeline Products for Bone Metastasis - Comparative Analysis 11
Bone Metastasis - Therapeutics under Development by Companies 12
Bone Metastasis - Therapeutics under Investigation by Universities/Institutes 13
Bone Metastasis - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Bone Metastasis - Products under Development by Companies 17
Bone Metastasis - Products under Investigation by Universities/Institutes 18
Bone Metastasis - Companies Involved in Therapeutics Development 19
Ablynx NV 19
Alethia Biotherapeutics Inc. 20
Amgen Inc. 21
Amura Holdings Limited 22
Bayer AG 23
BiologicsMD, Inc. 24
ChemoCentryx, Inc. 25
Deciphera Pharmaceuticals, LLC 26
Oncobiologics, Inc. 27
Oncodrone BV 28
Osteologix Holdings Plc. 29
R-Pharm 30
Taiho Pharmaceutical Co., Ltd. 31
Terpenoid Therapeutics Inc 32
Bone Metastasis - Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Target 34
Assessment by Mechanism of Action 36
Assessment by Route of Administration 38
Assessment by Molecule Type 40
Drug Profiles 42
AB-25E9 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
ADM-01 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
ALX-0141 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
AM-3701 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
AMG-161 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
BKM-1644 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
BKM-1740 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
BMD-3151 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
CCX-354 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
DCC-3014 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
denosumab - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
denosumab biosimilar - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
Drugs to Inhibit CXCL5 for Bone Metastasis and Breast Cancer - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
LG-1980 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
Monoclonal Antibodies to Inhibit SVEP1 for Bone Metastasis - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
NBS-101 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
OCD-155 - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
radium Ra 223 dichloride - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
Recombinant Protein for Bone Metastasis and Non-Small Cell Lung Cancer - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
roneparstat - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
RPH-203 - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
RSF-102 - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
RSF-103 - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
Small Molecules to Inhibit cFMS Kinase for Immunology and Oncology - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
Small Molecules to Inhibit GGDPS for Bone Metastasis and Oncology - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
TAS-115 - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
TPH-9 - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
vicrostatin - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
Bone Metastasis - Dormant Projects 88
Bone Metastasis - Discontinued Products 91
Bone Metastasis - Product Development Milestones 92
Featured News & Press Releases 92
May 18, 2016: Bayer to Showcase Latest Data on Xofigo (radium Ra 223 dichloride) at ASCO 2016 92
Mar 29, 2016: Bayer Receives Approval for Xofigo in Japan 93
Feb 03, 2016: NICE issues full guidance for Xofigoq (radium-223 dichloride) 94
Sep 14, 2015: Bayer to Present Data On Radium-223 Dichloride at ECC2015 in Vienna 95
Jul 06, 2015: R-Pharm Group of Companies Develops Original drug for Treatment of Metastatic Bone Disease 96
Oct 09, 2013: Medivir: Positive results from a phase I study with MIV-711 for the treatment of osteoarthritis and other bone related disorders 97
Oct 01, 2013: Goodwin Biotechnology Announces the Return of AB-25E9 Monoclonal Antibody Project from Alethia Biotherapeutics 98
Jul 17, 2013: The New England Journal of Medicine publishes results from the phase III ALSYMPCA study of Xofigo 98
Jun 20, 2013: Algeta Opens Commercial Production Facility For Xofigo Injection In Kjeller, Norway 99
May 30, 2013: Algeta Announces First Sale Of Xofigo In US 100
Feb 15, 2013: Algeta Presents Further Sub-analysis Of Phase III ALSYMPCA Study Of Radium-223 Dichloride At 2013 Genitourinary Cancers Symposium 101
Jan 14, 2013: US Nuclear Regulatory Commission Issues Licensing Decision For Radium-223 Dichloride 102
Sep 17, 2012: Bayer To Present Data On Alpharadin At ESMO 2012 Congress 102
Aug 21, 2012: Medivir Commences Phase Ib Trial Of MIV-711 For Treatment Of Skeletal Disorders 103
Jun 04, 2012: Bayer Reports Updated Data From Phase III Study Of Alpharadin For Treatment Of Prostate Cancer 103
Appendix 106
Methodology 106
Coverage 106
Secondary Research 106
Primary Research 106
Expert Panel Validation 106
Contact Us 106
Disclaimer 107

List of Tables

Number of Products under Development for Bone Metastasis, H2 2016 10
Number of Products under Development for Bone Metastasis - Comparative Analysis, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Number of Products under Investigation by Universities/Institutes, H2 2016 13
Comparative Analysis by Late Stage Development, H2 2016 14
Comparative Analysis by Clinical Stage Development, H2 2016 15
Comparative Analysis by Early Stage Development, H2 2016 16
Products under Development by Companies, H2 2016 17
Products under Investigation by Universities/Institutes, H2 2016 18
Bone Metastasis - Pipeline by Ablynx NV, H2 2016 19
Bone Metastasis - Pipeline by Alethia Biotherapeutics Inc., H2 2016 20
Bone Metastasis - Pipeline by Amgen Inc., H2 2016 21
Bone Metastasis - Pipeline by Amura Holdings Limited, H2 2016 22
Bone Metastasis - Pipeline by Bayer AG, H2 2016 23
Bone Metastasis - Pipeline by BiologicsMD, Inc., H2 2016 24
Bone Metastasis - Pipeline by ChemoCentryx, Inc., H2 2016 25
Bone Metastasis - Pipeline by Deciphera Pharmaceuticals, LLC, H2 2016 26
Bone Metastasis - Pipeline by Oncobiologics, Inc., H2 2016 27
Bone Metastasis - Pipeline by Oncodrone BV , H2 2016 28
Bone Metastasis - Pipeline by Osteologix Holdings Plc., H2 2016 29
Bone Metastasis - Pipeline by R-Pharm, H2 2016 30
Bone Metastasis - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2016 31
Bone Metastasis - Pipeline by Terpenoid Therapeutics Inc, H2 2016 32
Assessment by Monotherapy Products, H2 2016 33
Number of Products by Stage and Target, H2 2016 35
Number of Products by Stage and Mechanism of Action, H2 2016 37
Number of Products by Stage and Route of Administration, H2 2016 39
Number of Products by Stage and Molecule Type, H2 2016 41
Bone Metastasis - Dormant Projects, H2 2016 88
Bone Metastasis - Dormant Projects (Contd..1), H2 2016 89
Bone Metastasis - Dormant Projects (Contd..2), H2 2016 90
Bone Metastasis - Discontinued Products, H2 2016 91